Category: Drug Discovery
Drug Discovery market research reports by Roots Analysis
-
Aptamers: Therapeutics, Technologies, and Services Market, 2022-2035
Aptamers: Therapeutics, Technologies, and Services Market, 2022-2035 Post the approval of the first aptamer-based therapy, Macugen®, by the US Food and Drug Administration (USFDA) in December 2004, there has been a significant increase in the R&D initiatives focused on evaluating the potential o ... Read More
-
Next Generation Complement Therapeutics Market, 2022-2035: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), Therapeutic Area (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), Type of Molecule (Biologic and Small Molecule), Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Oral and Subcutaneous), Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035
Next Generation Complement Therapeutics Market, 2022-2035: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis ... Read More
-
Immune Checkpoint Inhibitors (PD-1 & PD-L1 Targeting Drugs): Analysis of Clinical Trial Results (Featuring Insightful Summaries of Recently Published Trial Results, Contemporary Pipeline Review, Clinical Trial Analysis, Clinical Publications Analysis, and Estimated Time to Market Analysis for Novel Drug Candidates)
Immune Checkpoint Inhibitors (PD-1 & PD-L1 Targeting Drugs): Analysis of Clinical Trial Results (Featuring Insightful Summaries of Recently Published Trial Results, Contemporary Pipeline Review, Clinical Trial Analysis, Clinical Publications Analysis, and Estimated Time to Market Analysis for No ... Read More
Research Assistance
